ralwel / iStockphoto.com
Several recent cases from the US Court of Appeals for the Federal Circuit offer guidance on navigating the §101 legal framework with respect to CRISPR patent claims, as Pat Carson and Mira Atanassova Mulvaney of Kirkland & Ellis report.
The CRISPR gene manipulation system—an adaptive immune system used by microbes to defend against viruses, which has been repurposed into an efficient and reliable gene-editing technique in mammalian cells—has taken the genome engineering world by storm and has attracted much attention for its immense promise in the development of innovative diagnostic tools and therapies.
Since the filing of the first patent claiming CRISPR as a gene-editing tool in 2012, the US Patent and Trademark Office (USPTO) has granted more than 1,000 patents pertaining to CRISPR in some form, and over 600 applications with claims pertaining to CRISPR remain pending.
Building on the original CRISPR patents, which modestly claimed methods of sequencing certain CRISPR regions, and similarly narrow applications encompassing strain typing, phage resistance and uses in bacteria, the current CRISPR patent landscape appears enormously varied, both in terms of the patentees and applicants involved and the types of claims sought.
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
Cooley
European Patent Office
Finnegan LLP
GH Research
Gowling WLG
George Washington Law School
HGF Limited
IQVIA
Kirkland & Ellis International LLP
Marks & Clerk
Mintz Levin
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
Taylor Wessing
The United States Patent and Trademark Office (USPTO)
Valea AB
World Intellectual Property Office
For multi-user price options, or to check if your company has an existing subscription we can add you into for FREE, please contact Atif at achoudhury@newtonmedia.co.
If you have any technical issues please email tech support.
CRISPR, Kirkland & Ellis, Pat Carson, Mira Atanassova Mulvaney, immune system, gene manipulation, microbes, viruses, gene-editing, genome engineering